Elixirgen Therapeutics received FDA Rare Pediatric Disease Designation for EXG-34217, a treatment for dyskeratosis congenita and related telomere biology disorders (DC/TBD).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.